TTrialPathMatch Me to Trials
← Back to trials
RecruitingMultiple Myeloma

Sirolimus Pre-conditioning on T Cell Activity and T-cell Engaging Bispecific Antibody Efficacy in Multiple Myeloma

Eligible age

18+ yrs

Accepts

All genders

Locations

1 state

Healthy volunteers

No

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

This is a single center, single arm Phase Ib study with expansion cohort designed to establish the safety and physiologic effects of sirolimus pre-conditioning followed by T-cell engaging bispecific antibody therapy.

Sponsor: Christopher Strouse

You may qualify if…

  • ✓ To be eligible to participate in this study, an individual must meet all of the following criteria:
  • ✓ Willingness and ability to provide signed and dated informed consent form.
  • ✓ Stated willingness to comply with all study procedures and availability for the duration of the study.
  • ✓ Aged 18 years of older.
  • ✓ Diagnosis with multiple myeloma, per IMWG Consensus Criteria.20
  • ✓ Planned for treatment with teclistamab, or talquetamab per standard of care, label indications.15
  • ✓ Prior exposure to any of the following types of T-cell engaging therapies.
  • ✓ 1. Anti-BCMA x CD3 bispecific antibody (for example: teclistamab, elranatamab)

You may not qualify if…

  • ✕ An individual who meets any of the following criteria will be excluded from participation in this study:
  • ✕ Participants whose multiple myeloma is progressing at a rapid pace requiring immediate anti-myeloma therapy per assessment by the principal investigator or enrolling investigator are excluded.
  • ✕ Excluded concomitant medication exposures:
  • ✕ Exposure to corticosteroids within 1 week of treatment start
  • ✕ Exposure to calcineurin inhibitor or mTOR inhibitors (tacrolimus, everolimus, temsirolimus, sirolimus)
  • ✕ Immunomodulatory monoclonal antibodies targeting tumor necrosis factor alpha (e.g. infliximab), interleukin 6 (e.g. siltuximab),
  • ✕ Janus kinase inhibitors (e.g. ruxolitinib)
  • ✕ Any other investigational drug within 28 days

Where it's recruiting

Iowa

Iowa City

Source: ClinicalTrials.gov · NCT07581704 · last updated 2026-06-04

Sirolimus Pre-conditioning on T Cell Activity and T-cell Engaging Bisp · TrialPath